Autopsy report · NCT06408168
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
Cause of deathSlow enrollment
“\<75% Participation”
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year 4 months before it stopped.
- 6 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negative; Metastatic Invasive LObular Carcinoma
- Interventions
- Fulvestrant; Repotrectinib
- Participants
- 6
- Sites
- 1
- Countries
- United States
Trials that died the same way
- ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
“\<75% participants” - Vapocoolant Analgesia for Breast Lymphoscintigraphy
“\<75% accrued participants” - Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery
“low participation rate” - Physiotherapy and Therapeutic Education After Total Knee Arthroplasty.
“low participation” - Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy
“Lack of participations (8 of 25)”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.